Your cart is empty.

Celebrating 22 YEARS of Regulatory Excellence!
Go with the Most-Trusted Regulations & Guidelines Books on the Market.

Now Taking Advance Orders for our Revised APRIL 1, 2024 Books!      Also check out our NEW Book:  Good Clinical Practice Regulations in the US & the EU  (Book 1C)!

Book 1B:  2023 FDA Good Clinical Practice Guide

Book 1B: 2023 FDA Good Clinical Practice Guide

$ 19.95

Return to Previous Page

This spiral-bound, 5" x 7.5" book is a compilation of the FDA Good Clinical Practice regulations (21 CFR Parts 11, 50, 54, 56, and 312) and ICH Guidelines (E6, E2A, and E8), as well as the FDA Information Sheets and other guidance documents that govern the conduct of clinical trials for drug research.  Please note that this book does NOT contain the sections of 21 CFR Part 314 on New Drug Applications (NDAs).  21 CFR Part 314 is contained in its entirety in Book 1A, Selected Regulatons and Guidance for Drug Studies.

Who Uses this Book and How?
• Clinical Research staff, as job aids
• Training departments, as training handouts
• Human Resources, as part of new-employee orientation
• Legal/Regulatory/QA staff, for company-wide distribution

What's the Price?
• 1-99 copies:  $19.95             • 100-249 copies:  $18.95
• 250-499 copies: $17.95          • 500+ copies:  $16.95

Custom Cover Prices*?
• 1-24 copies:  unavailable             • 25-100 copies:  $2.00/book
• 100-249 copies: $1.00/book        • 250+ copies:  No charge

* Based on quantities of a single book title

•  Index to 21 CFR Parts 11, 50, 54, 56, 312, 314

•  CFR Title 21:  Food and Drugs (Revised as of April 2023)

11    Electronic Records/Electronic Signatures
50    Protection of Human Subjects
54    Financial Disclosure
56    Institutional Review Boards
312  Investigational New Drug Application
314  Sections 314.80, 314.81: Post-Marketing Reporting
Section 314.126: Adequate and Well-Controlled Studies 

•  FDA INFORMATION SHEETS:  Guidance for IRBs, Clinical Investigators and Sponsors 

Includes guidance on Informed Consent, Subject Recruitment, Payments to Study Subjects, Subject Screening Tests, and Treatment Use of Investigational Drugs.

•  ICH Guidelines (US, Step 5)

E6(R2)     Good Clinical Practice (Includes R2 Addendum)
E2A  Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
E8(R1)     General Considerations for Clinical Trials

• Additional FDA Guidance Documents:

• Selected Drug Development Web Sites (Revised 2023)
• Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring
• FDA Compliance Program Guidance #7348.810: Sponsors, CROs & Monitors
• Adverse Event Reporting to IRBs - Improving Human Subject Protection
• Safety Reporting Requirements for INDs and BA/BE Studies

• European Directives on GCP (2001 and 2005) 

Click here to see an enlarged pdf cover